Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Differential identification of Entamoeba spp. based on the analysis of 18S rRNA.

Santos HL, Bandea R, Martins LA, de Macedo HW, Peralta RH, Peralta JM, Ndubuisi MI, da Silva AJ.

Parasitol Res. 2010 Mar;106(4):883-8. doi: 10.1007/s00436-010-1728-y. Epub 2010 Feb 19.

PMID:
20169364
2.

KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer.

Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB.

Ann Surg Oncol. 2010 Feb;17(2):416-24. doi: 10.1245/s10434-009-0713-0. Epub 2009 Oct 8.

3.

KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.

Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny N, Paty PB.

Ann Surg Oncol. 2010 Feb;17(2):572-8. doi: 10.1245/s10434-009-0605-3. Epub 2009 Sep 1.

PMID:
19727962
4.
5.

Cellular physiology of STAT3: Where's the cytoplasmic monomer?

Ndubuisi MI, Guo GG, Fried VA, Etlinger JD, Sehgal PB.

J Biol Chem. 1999 Sep 3;274(36):25499-509.

6.

Regulation of IL-6 signaling by p53: STAT3- and STAT5-masking in p53-Val135-containing human hepatoma Hep3B cell lines.

Rayanade RJ, Ndubuisi MI, Etlinger JD, Sehgal PB.

J Immunol. 1998 Jul 1;161(1):325-34.

7.

Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability.

Ndubuisi MI, Patel K, Rayanade RJ, Mittelman A, May LT, Sehgal PB.

J Immunol. 1998 Jan 1;160(1):494-501.

8.

Interleukin-6 chaperones in blood.

May LT, Ndubuisi MI, Patel K, García D.

Ann N Y Acad Sci. 1995 Jul 21;762:120-8.

PMID:
7668523
9.

Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy.

May LT, Patel K, García D, Ndubuisi MI, Ferrone S, Mittelman A, Mackiewicz A, Sehgal PB.

Blood. 1994 Sep 15;84(6):1887-95.

PMID:
8080995

Supplemental Content

Loading ...
Support Center